Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Impact · against what's priced in

Vir Biotechnology will dilute existing shareholders to raise $150 million. While the capital provides runway for clinical operations, the immediate issuance of 15 million shares at $10.00 creates a negative near-term price catalyst.

VIR−0.30

No priced-in read yet

In context

The pricing of 15 million shares at $10.00 per share introduces immediate dilution, though it secures $150 million in liquidity for the company's clinical operations.

Read from the article alone

• public offering▲500%
• pharmaceuticals
• biotech
• VIR
• capital raise
• common stock
• equity offering

Top 1 mover · tap to explore